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AIM
The  present  randomized  double  blind  study  was 
designed  to  evaluate  the  effects  of  addition  of  morphine  to 
hyperbaric  bupivacaine  given  intrathecally  to  patients 
undergoing elective abdominal hysterectomy.
1. To compare the efficacy of two different doses i.e, 
150mcg and 250 mcg of intrathecal morphine with 
bupivacaine in terms of duration of   analgesia, time 
to  first  dose  of  rescue  analgesia,  total  dose  of 
rescue analgesic medication required for the first 24 
hours.  
2. To  compare  the  incidence  and  severity  of  side 
effects after administration of 150 mcg and 250 mcg 
intrathecal morphine.
 
INTRODUCTION
Spinal  anesthesia  continues to be one of  the commonest 
regional  anesthetic  techniques because of  its  rapid  onset,  safety 
and  simplicity.  Ignored  until  the  late  twentieth  century  as  a 
substrate for analgesia, the spinal cord has now emerged as one -if 
not the key target for pain control in clinical anesthesiology. More 
and more anesthesiologists  now give drugs spinally to  provide 
intraoperative anesthesia and post operative analgesia in various 
surgical procedures.
The use of neuraxial opioids has increased dramatically in 
recent  years,  augmenting  the  analgesia  produced  by  local 
anesthetics by binding directly to opiate receptors. Animal and 
human  studies have indicated that opioids and local anesthetics 
administered  spinally  have  a  synergistic  analgesic  effect.  The 
synergistic  action  of  local  anesthetics  and  morphine  is  well 
known,  morphine  probably  more  superior  for  post  operative 
analgesia, when compared to other opioids.
Preservative-free  morphine  is  now  available  in  India 
making  intrathecal  administration  possible.  The  present 
randomized double blind study was designed to evaluate the 
effect  of  adding  preservative  free  morphine  to  hyperbaric 
bupivacaine given intrathecally for abdominal hysterectomy. In 
India, most of  the abdominal  hysterectomies are done under 
regional  anesthesia.  By  adding  morphine   along  with  local 
anesthetic,  the  duration  of  analgesia  can  be  increased  with 
minimum side effects and this  is also cost- effective.
REVIEW OF LITERATURE
International  Association  for  the  Study  of  Pain  (IASP)1 
defines pain as an unpleasant sensory and emotional experience 
associated with actual or potential  tissue damage or described in 
terms of such damage.
Acute pain in the perioperative setting has been defined as 
“pain that is present in a surgical patient because of preexisting 
disease, the surgical procedure (e.g.- associated drains, chest or 
nasogastric  tubes,  complications)  or  a  combination  of  disease 
related and procedure-related sources”. (ASA task force on pain 
management)2
Acute postoperative pain  is  a complex reaction to tissue 
injury,  visceral  distention  or  disease.  It  is  a  manifestation  of 
anatomical and physiological responses that result in unpleasant 
sensory and emotional experiences.
Pa  thophys  iological consequences of pain  3   
1. Cardiovascular  system  -  tachycardia,  hypertension, 
increased  systemic  vascular resistance  and  increased 
cardiac work.
2. Pulmonary  system  -  hypoxia,  hypercarbia,  atelectasis, 
decreased  cough,  vital  capacity,  functional  residual 
capacity, and ventilation perfusion mismatch.
3. Gastrointestinal tract - nausea, vomiting and ileus.
4. Renal - oliguria and urinary retention.
5. Extremities - skeletal muscle pain and limited mobility.
6. Endocrine - vagal inhibition,  increased adrenergic activity, 
metabolism and   oxygen consumption.
7. CNS - anxiety, fear, sedation and fatigue.
8. Immunological - impairment
This list is a compelling reason why postoperative pain must be 
treated effectively.
Rationale of Postoperative Pain Relief
Aim  of  postoperative  pain  treatment  is  to  provide 
subjective  comfort  in  addition  to  inhibiting  trauma  induced 
nocioceptive impulses. This is in order to  blunt  autonomic and 
somatic reflex responses to pain and subsequently to  enhance 
restoration of function by allowing the patient to breathe, cough 
and move more easily.
Pain  control  may  have  a  further  benefit  of  improving 
clinical  outcome  by  reducing  the  incidence  of  postoperative 
complications  such  as  myocardial  infarction  or  ischaemia, 
impaired  wound  healing,  risk  of  atelectasis,  thrombo-embolic 
events, peripheral vasoconstriction and metabolic acidosis.
Effect of post operative analgesia on surgical outcome
Optimal  (dynamic)  pain  relief  is  a  prerequisite  for  early 
postoperative  recovery.  A  reduction  in  the  surgical  stress 
responses (endocrine, metabolic and inflammatory) will lead to a 
reduced incidence of postoperative organ dysfunction and thereby 
to an improved outcome4.
Pharmacological management
During  recent  years,  there  has  been  a  tremendous 
increase in our  understanding of  the physiology of  acute pain, 
development of new analgesics and techniques of administration5.
Various routes  available  for  postoperative pain control 
include  intramuscular,  subcutaneous,  intravenous,  oral,  rectal, 
transdermal, epidural, intrathecal, caudal etc.
The commonly used drugs are opioids and NSAIDs.  The 
delivery  could  be  in  the  form  of  intermittent  boluses  or 
continuous infusion or patient-controlled administration( PCA).
A)      Systemic Opioids
Opioid analgesics are usually used to relieve moderate to 
severe  pain particularly of visceral origin. In addition to relief of 
pain,  morphine  also  confers  a  state  of  euphoria  and  mental 
detachment.
Morphine is a centrally acting exogenous opioid agonist 
that  mimics  the  activity  of  the  endogenous  opioid  peptides.  It 
exerts its  analgesic effect  by acting in 2 places along the pain 
pathway. First, morphine binds at u receptors in the nocioceptive 
synapse of the spinal cord; this inhibits the release of substance 
P  and  hyperpolarizing  postsynaptic  interneurons,  thus 
decreasing the transfer of the pain signals across the synapse. 
Second,  morphine  binds  to  u  receptors  in  the  brainstem, 
activating the descending analgesic  pathway that  inhibits  signal 
transduction across the nocioceptive synapse in the spinal cord.6 
Morphine is primarily metabolized in the liver by glucuronidation 
to  morphine-3-glucuronide  (M3G;  a  mostly  inactive  metabolite) 
and  to  morphine-6-glucuronide  (M6G;  a  highly  active 
metabolite).  M6G  exhibits  similar affinity  for  u receptors  and 
displays  an  analgesic  potency  equal  or  superior  to  that  of 
morphine. Like morphine, M6G  crosses the blood-brain barrier 
and has been found to prolong the effects of morphine in long-
term  use.7 Respiratory  depression  (rate,  tidal  volumes,  and 
carbon  dioxide  sensitivity)  results  from  direct  action  on  u 
receptors of the pontine and bulbar brainstem respiratory center 
that  inhibits  normal  (reflex)  responses to increasing levels  of 
carbon  dioxide.8 Morphine  may  cause  arterial  and  venous 
dilatation  due  either  to  direct  activity  or  histamine  release. 
Morphine  induces  impairment  of  compensatory  sympathetic 
nervous  system  responses  thereby  causing  orthostatic 
hypotension. Morphine's action on u receptors of colonic smooth 
muscle cells increases tonic contractions, but reduces the rate of 
propulsive  waves,  leading  to  delayed  transit  time  and 
constipation.  Nausea  and  vomiting  are  induced  by  morphine's 
activation of the u receptors in the chemoreceptor trigger zone 
(CTZ) in the area  postrema of the medulla; the CTZ is one of 
many sensory inputs that stimulate the vomiting centre.9
LIMITATIONS OF OPIOID ANALGESIA 
1)Respiratory depression, sedation and impaired consciousness.
2)Inadequate pain relief on movement postoperatively.
3)Gastrointestinal-frequent  nausea  and  vomiting,  postoperative 
ileus and reduced intestinal secretion.
4)  Reductions of REM sleep in early postoperative period.
5)  Urinary retention.
6)Histamine   release, causing skin flushing   and hypotension.
7)Drug abuse
B) NSAID
Pharmacological  management  of  mild  to  moderate 
postoperative pain normally is initiated with NSAIDs, unless there 
is a contraindication to NSAIDs11.
NSAIDs  decrease  levels  of  inflammatory  mediators 
generated at the site of tissue injury. NSAIDs block prostaglandin 
synthesis, thus preventing this compensatory response and inhibit 
platelet aggregation. This raises the concern for potential bleeding 
complications  when  they  are  used  perioperatively.  NSAIDs 
have  several  advantages  over  opioids.  They  do  not  have 
hemodynamic side effects; do not cause  respiratory depression, 
or slow gastric emptying or small-bowel transit  time. In addition, 
preemptive  use  of  NSAIDs  can  virtually  eliminate  effects 
associated  with  activation  of  NMDA  receptors.  NSAIDs  may 
cause  significant  renal  impairment,  particularly  in  patients  with 
renal disease or decreased circulating blood volume. 
Limitations of NSAID Analgesia
NSAIDs inhibit prostaglandin synthesis.
1)Patients with peptic ulceration, renal impairment and asthma, if 
given  NSAIDs  may  have  drug  induced  exacerbations  of  these 
diseases.
2)NSAIDs may cause increased surgical bleeding. NSAIDs are not 
very effective against visceral pain in contrast to the somatic pain 
where they are very effective.
C) Central Neuraxial blockade
Epidural,  subarachnoid  and  caudal  routes  have  been  used  to 
provide postoperative analgesia.
Inadequate Pain Relief 
Analgesia  for  postoperative  pain  has  traditionally  been 
provided with oral or intramuscular opioids. However, despite the 
widespread belief  that  intramuscular  opioids  provide  acceptable 
pain  relief,  approximately  75  percent  of  hospitalized  patients 
receiving  intramuscular  opioids  remain  in  moderate  to  severe 
pain12.
In  contrast  to  the  inadequacy  of  traditional  analgesic 
therapy, newer analgesic techniques can prevent or easily control 
postoperative  pain  in  most  patients.  Still  there  are  so  many 
patients who continue to experience moderate to severe pain after 
surgery, one of the primary causes appears to be the perception 
that  pain  is  a  natural,  inevitable  accompaniment  to  illness  and 
disease.  Indeed,  most patients,  physicians and nurses consider 
moderate  to  severe  postoperative  pain  to  be  an  acceptable 
consequence of surgery.13
Another important factor contributing to under treatment is 
that pain is `invisible’ in most hospital wards, severity of pain is not 
assessed,  and  patients  are  reluctant  to  "complain."  Unless 
severity of pain is assessed on a routine basis, pain cannot be 
effectively treated. Thus, one of the most important changes in the 
process of improving the efficacy of pain treatment is to introduce 
pain assessment as the “fifth vital sign” in addition to the traditional 
four vital signs (temperature, pulse, blood pressure and respiratory 
rate).  Pain  assessment  should  be  frequent  and  can  be  simply 
accomplished using a verbal descriptive scale or a visual analog 
scale.
Recognizing that pain is important enough to be measured 
and recorded, is the first step in changing attitudes and improving 
pain management for our patients.
Therapeutic Options for optimal postoperative analgesia
Selecting the most optimal method to control postoperative 
pain is an individualized prescription based upon the physiological 
status of the patient, the extent of surgical injury, and the technical 
expertise of the caregivers and the economical resources of the 
hospital.
The  following  methods  have  been  suggested  to  provide 
postoperative analgesia for patients having intermediate surgery 
(e.g.,  cesarean  section,  abdominal  hysterectomy,  radical  retro 
pubic prostatectomy, appendectomy, total joint replacement)
1)Traditional  intramuscular  opioid  analgesia  has  been 
demonstrated  to  provide  inadequate  analgesia  in  most  patients 
and has low patient satisfaction.
2)In this group of patients, the major advance in pain therapy has 
been intravenous patient-controlled analgesia (PCA) with opioids. 
Intravenous  PCA-administered  opioids  result  in  improved  pain 
scores,  improved  patient  satisfaction  and  a  more  constant 
analgesia. Although intravenous PCA may  not reduce morbidity 
and  mortality,  the  outcomes  of  improved  analgesia  and  better 
patient  satisfaction  suggest  that  it  is  the  therapy  of  choice  in 
hospitalized patients with moderate-to-severe postoperative pain.14
3)The  addition  of  parenteral  or  oral  NSAIDs  has  been 
demonstrated  to  decrease  requirements  for  intravenous  PCA 
opioids  and  to  speed  recovery  of  bowel  function  after  intra-
abdominal surgery.15
4)  Infiltration  of  the  surgical  wound  or  the  peripheral  nerves 
innervating the wound with bupivacaine  0.125 to 0.25 percent can 
provide  profound  postoperative  analgesia  with  minimal  adverse 
side  effects.  Wound  infiltration  can  also  provide  benefit  when 
combined with general  anesthesia.  There have been theoretical 
concerns  that  local  infiltration  might  impair  wound  healing  or 
increase  the  risk  of  infection.  These  complications  are  not 
increased  in  clinical  trials  of  infiltration  analgesia.  Wound 
infiltration  is  an  extremely  valuable  and  currently  underutilized 
technique for postoperative analgesia.
5)      Finally, single injections of epidural or intrathecal opioids  at 
the time   of surgery have shown to  provide better pain relief than 
intravenous  PCA opioids.  They  also  appear  to  improve  patient 
satisfaction  and   postoperative  outcome  in  various  surgical 
procedures16. 
6)  The introduction of  intrathecal  and epidural  opioids marks 
one of the most important breakthroughs in pain management in 
the  last  two  decades.  Profound  segmental  antinociception  is 
obtained  with  doses  much  smaller  than  would  be  required  if 
administered  systemically.  However,  a  wide  variety  of  clinically 
relevant  non-nociceptive side effects may occur,  some of which 
are minor, while others are potentially lethal.
In  the  past  decade,  literature  citations  have  shown  the 
effectiveness of spinally administered opioids and their ability to 
provide  powerful  regional  analgesia  without  associated  motor 
blockade, sensory autonomic deficits or excessive central nervous 
system depression.
Historical perspective:  With the discovery by Pert and Snyder 
in  1973  of  specific  opioid  receptors  and  their  subsequent 
identification in the substantia gelatinosa of the spinal cord, the 
stage  was  set  for  the  clinical  application  of  opioids  to  the 
subarachnoid or epidural space17.
The  discovery  of  "selective"  mechanism  for  pain  inhibition  at 
spinal cord level has opened up a new era of options for acute and 
chronic  pain  management.  Evidence  of  a  selective  spinal 
analgesic  effect  of  opioids  in  humans  is  provided  by  two 
electrophysiological  studies  of  spinal  cord  function  after 
intravenous morphine,  by pharmacokinetic  studies and by various 
indirect studies of changes of neurologic function after intrathecal 
and epidural opiates.
In  1979  Wang  et  al  reported  the  first  use  of  spinal 
intrathecal  opioids  in  humans in  the context  of  a double  blind 
placebo controlled cross over study.  8 patients with intractable 
pain due to malignancies of the genitourinary tract with invasion 
of the lumbosacral plexus received morphine 0.5 or 1 mg and 
physiologic saline at the 2nd or 3rd lumbar interspace to a total of 
17 and 12 injections respectively.  2 patients reported pain relief 
after  separate  injections  of  morphine  and  saline  although  the 
duration of pain relief after morphine was 15 hrs, whereas that 
after  saline  injection  was  only  7  hrs.  This  incidence  (25%)  of 
placebo  effect  and  duration  of  effect  is  in  keeping  with  many 
previous studies.
Cousins et al coined the term "selective spinal analgesia" 
which refers to the presence of analgesia without motor, sensory 
or  autonomic  deficits18.  They  reported  that  1-2  mg  morphine 
injected in the thoracic  region  close to  appropriate  spinal  cord 
segments relieved the pain of breast cancer and lung cancer for 
24-48 hours.
Ventrafridda et al employed either cervical (C3-5) or lumbar 
(L3-4) injections of morphine 1 mg in 1 ml in 30 cancer patients, all 
of  whom  had  their  pain  relieved.  However,  they  reported  that 
drowsiness, orthostatic dizziness, itching, sweating and nausea 
were frequent side effects.
Use of intrathecal opioids for acute and chronic pain relief 
subsequently  were  reported in many clinical  settings,  including 
post  operative pain,  cancer  pain,  chronic  pain,  obstetrics,  post 
myocardial infarction19.
Definitive neurophysiological studies performed in the early 
1970's  demonstrated that  morphine selectively suppressed dorsal 
horn lamina I and V neurons, which mediate noxious information, 
yet had no effect on lamina IV neurons, which process light touch 
and  proprioceptive  input.  Encephalin  containing  neurons  and 
opioid  receptors  were  almost  exclusively  localized  to  the 
substantia  gelatinosa  provided  evidence  of  an  intrinsic  spinal 
modulatory  system whose  activation  could  attenuate  release  of 
substance  P  and  other  nociceptive  transmitters.  Spinal  opioid 
analgesia  avoided  the  hypotension,  convulsions  and  risk  of 
cardiovascular  collapse  associated  with  the  use  of  local 
anesthetics20.
Site of Action of Spinal opioids:  The weight of evidence now 
points  to  the dorsal  horn as  one main site of  action of  spinal 
opioids based upon
i. iontophoretic and micro injection data that show a strong 
focus of activity in the substantia gelatinosa.
ii. autoradiographs  following  application  of  radio-labeled 
morphine or fentanyl to the surface of the spinal cord show 
that the front of radioactivity corresponds to the substantia 
gelatinosa  at  a  time  when  the  discharge  of  lamina  V 
neurons to noxious stimuli was reduced significantly.
iii. latencies  for  inhibition  of  lamina  V  neurons  following 
intrathecal  administration of  morphine are similar to those 
reported for the latency to block the skin twitch response 
following intrathecal morphine in the cat. Also it is likely that 
there  is  both  presynaptic  and  postsynaptic  inhibition  of 
primary afferent transmission in the spinal cord.
Neurotoxic  potential:  Solutions  of  opioids  of  potential  use  in 
spinal  injections  (morphine,  methadone,  meperidine,  fentanyl, 
alfentanil,  lofentanil,  buprenorphine)  and  local  anesthetics  in 
normal saline had pH in the range of 4.52-6.85. When mixed with 
CSF,  all  lowered  pH of  the CSF by 0.3 or  less.  No histologic 
evidence of cord pathology was found in animal studies19.
Characteristics  of  spinal  receptor  populations  acted upon by 
spinal opiates:
The premise that opiates act upon a specific spinal receptor 
site to produce the antinociception observed following intrathecal 
administration is based exclusively on the pharmacologic profile of 
the  effects  produced  by  spinally  administered  opiates.  In 
general,  these  effects  are  dose  dependent,  stereospecific, 
antagonized by naloxone and have a structure activity relationship 
which  closely  resembles  that  observed  with  systemically 
administered agents. In a work by Martin et al, three classes of 
opiate  receptors i.e. mu, kappa and sigma were postulated on the 
basis  of  different  pharmacological  profiles  for  morphine, 
ketocyclazocine and SKF 10047 respectively. Lord et al proposed 
the existence of mu and delta receptors.
Certain  opiates  have local  anesthetic  properties.  With the 
high  local  concentration  achieved  by  a  spinally  administered 
agent,  drug  concentration  sufficient  to  induce  non-specific 
alterations  in  membrane  ionic  permeability  could  be  achieved21 
Opioid receptors are coupled to guanosine (G) effector  proteins 
which mediate the changes in calcium and potassium ion flux and 
membrane  polarity  necessary  to  modulate  nociceptive  input. 
Activation of kappa receptors directly inhibits Substance P release 
at primary afferent terminals by blocking calcium influx  required 
for transmitter release. Mu and delta receptors appear to be coupled 
to voltage dependent potassium channels. Stimulation  of  mu and 
delta  receptors  leads to  increased potassium  conduction and 
neuronal hyperpolarization.
This  effect  is  mediated  by  G  protein  inhibition  of  cyclic 
adenosine  monophosphate  synthesis  and  directly  counters  the 
pronounced decrease in  potassium permeability  caused by the 
nociceptive transmitter substance P.
  Antinociception induced by morphine is mediated by 
stimulation of mu, delta and kappa receptors,  whereas fentanyl 
analgesia is mediated by mu receptors only. This ability to interact 
with a variety of receptor  subtypes may underlie  morphine's 
neuraxial specificity and high analgesic efficacy.
The term "affinity"  describes the attraction and successful 
attachment of opioid ligands to the binding site, whereas "efficacy" 
characterizes the ability to activate the effector mechanisms. The 
term  "potency"correlates  analgesic  response  versus  dose 
requirement  and  is  influenced  by  several  factors,  including 
receptor  binding affinity and intrinsic efficacy.  At the spinal level 
potency  is  also  related  to  gains  in  analgesic  effectiveness  as 
compared  with  systemic  administration  of  an  equivalent  dose. 
Spinal administration bypasses the blood brain barrier.  Hydrophilic 
opiates such as morphine have increased receptor  accessibility 
and  gains  in  analgesic  potency  relative  to  systemic 
administration.20
Genetic variability Klepstad et  al  in  their  short  review strongly 
argue  that  opioid  efficacy and  side-effects  are  partly  related  to 
inborn  properties  caused by genetic  variability  related  to  opioid 
metabolism, opioid receptors and opioid transporters. In addition, 
clinical effects may be influenced by variations in other biological 
systems that modify the effects induced by opioid agonists21. Alex 
T. Sia et al showed that the A118G polymorphism of the human 
mu-opioid  receptor  has  a  significant  effect  on  pain  perception, 
analgesic  requirement,  and  nausea  for  the  first  24  h  after 
cesarean delivery for patients  who had received intrathecal  and 
PCA intravenous morphine. Genetic variation at position 118 of the 
mu-opioid receptor is associated with inter individual differences in 
pain  scores,  self-administered  intravenous  morphine,  and  the 
incidence  of  nausea  postoperatively.  Further  research  and 
functional  studies  would  be  necessary  to  elucidate  the  clinical 
impact contributed by genetic variations22.
Spinal systems underlying spinal opiate analgesia:
The substrate upon which intrathecal opioids act to produce 
a  change  in  the  pain  threshold  can  only  be  implicated  if  the 
response  of  that  substrate  to  local  opiates  exhibits  the  same 
functional,  temporal  and  pharmacological  profiles  as  the 
analgesia. Thus intrathecal  opiates produce a significant elevation 
in the nociceptive threshold  with little effect at low doses (on the 
ability to perceive light touch) Similarly, spinal opiates at analgesic 
doses  have  little  effect  on  voluntary  motor  function  or  on 
monosynaptic reflex activity such as  manifested in tendon reflexes. 
These observations clearly suggest  that  intrathecal  opiates exert 
an effect on transmission through  systems activated by specific 
populations of primary afferents.
Factors affecting the time course of spinal opiate activity –
Onset  of  Analgesia:  The antinociceptive effects  of  agents  applied 
superficially to the spinal cord depend upon the movement of the 
agent from the surface to receptors associated with its activity. As 
the  ability  of  the drug  to  penetrate  into  brain  tissue has been 
closely  correlated  with  its  lipid  partition  coefficient,  the  time of 
onset of analgesia following intrathecal or epidural injection closely 
corresponds to the lipid partition coefficient of the agent and the 
pka.
Following intrathecal    injection the delay   in   onset of 
analgesia clearly indicates the minimum time for the drug to reach 
locus of action in the spinal cord in concentrations sufficient to 
produce a behaviourally significant change. A presumed site of 
action lies within the spinal gray. The rate of diffusion into tissue 
within limits varies directly with the lipid partition coefficient of the 
agent.23 Lipophilic  and weakly  ionized opioids rapidly  exit  the 
aqueous CSF  compartment  and  penetrate  into  lipid  rich  spinal 
tissue to activate opiate receptors.
In  contrast,  hydrophilic  opioids  such  as  morphine  have 
difficulty traversing neural  and vascular membranes and tend to 
remain in the cerebrospinal  fluid.  Morphine's  delay in  reaching 
spinal  sites  of  activity  underlies  its  observed  latency  to  clinical 
onset and peak analgesic effect. Additional delay has also been 
related  to  morphine's  low  intrinsic  efficacy  because  a  greater 
number of opioid receptors must be occupied to provide a similar 
intensity of spinal analgesia as that observed with potent agonist 
such  as  sufentanil.  Morphine's  globular  chemical  structure  is 
associated with less efficient transport than that observed with the 
more spindle shaped phenylpiperidine based opioids.20
Duration and Analgesic Efficacy:  Lipid solubility, polarity and the 
amount of unionized drug remaining in the CSF play key roles in 
determining  duration  of  spinal  analgesia5.  Though  the  extent  of 
metabolism is likely to be small compared to the concentrations 
present after  a bolus  intrathecal  injection,  the  metabolite  would 
render polar molecules such as morphine electrically neutral and 
therefore might enhance the clearance of the molecule from the 
brain.  With regard to the opiate peptides,  rapid metabolism has 
been noted as one of several variables limiting their activity.23
Clearance from epidural and intrathecal sites of deposition 
plays  a  major  role  in  determining  duration  of  action.  Principal 
routes of  clearance include both rapid vascular  absorption and 
slow rostral  diffusion in cerebrospinal fluid with elimination at the 
arachnoid  granulations.  Increasing  lipid  solubility  facilitates 
vascular  uptake,  therefore  this  route  of  clearance  has  greater 
importance with lipophilic opioids such alfentanyl and sufentanil. As 
significant  amounts  of  lipophilic  drug  are  taken  up  by  the 
epidural  venous  plexus  and  spinal  blood  vessels  or  become 
trapped in fatty tissues concentrations at sites of activity rapidly 
decline.  Morphine's  hydrophilic  properties  and  polarity  allow 
significant  amounts  of  drug  to  remain  sequestered  in  the 
cerebrospinal fluid for relatively long periods.
Receptor  dissociation  kinetics  also  influences  analgesic 
duration,  as  agents  associated  with  greater  drug-  receptor 
complex stability provoke prolonged activity. Total dose of opioid 
administered  and  volume  of  injectate  represent  two  additional 
variables which may influence duration of activity and dermatomal 
spread of analgesia.
Lack of rostral spread underlies fentanyl's segmental spinal 
analgesic  profile  that  results  from  its  rapid  incorporation  into 
epidural fat and vascular clearance from epidural and intrathecal 
sites  of  deposition.  Dermatomal  spread  of  lipophilic  opioids 
appears to be directly related to the dural surface area in contact 
with the drug and may be increased following administration of 
larger  volumes  of  solution20.  The  duration  of  action  is  dose 
dependant  with  lipid  soluble  agents  such  as  fentanyl  and 
meperidine having a shorter time course than more polar agents 
such as morphine.
Acutely, the duration of the antinociceptive effects observed 
following  intrathecal  or  epidural  opiates  following  acute 
administration is physically governed by metabolism of the drug to 
an inactive form,  or  by redistribution.  Chronically,  the absolute 
limitation to opiate-induced analgesia is the question of tolerance.
Model  of  Intrathecal  Opiates:  For  a  highly  ionized  and 
hydrophilic  drug  such  as  morphine,  intrathecal  injections  will 
produce  extremely  high  CSF  concentrations  which  will  move 
slowly out of the CSF into spinal cord receptor sites and into non 
specific binding sites and clearance sites (arachnoid granulations). 
Cephalad flow of CSF will cause redistribution of the injected drug 
up the spinal subarachnoid space to the brain. Low lipid solubility 
and slow uptake into spinal cord receptors results in slow egress 
of action. Slow egress from spinal cord results in a long duration of 
action.
In the case of a mostly ionized, lipid soluble drug such as 
fentanyl,  there  will  be  only  a  small  amount  of  unionized  lipid 
soluble  drug  in  CSF  after  subarachnoid  injection.  This  will 
penetrate  spinal  cord  receptors  and  nonspecific  binding  sites 
rapidly, but also will  have a rapid egress unless it has particular 
affinity for lipid or high receptor binding. Thus, for fentanyl (which 
is less than 10% unionized at pH 7.4), onset of analgesia is rapid, 
but duration is not as long as for morphine.
Advantages:  The particular  advantages which accrue from peri 
and postoperative spinal opiate analgesia are several.
i. The relief of painful input without motor blocks permits the post 
surgical  patient  to breathe freely and avoids the compromise of 
pulmonary  function  which  develops  when  the  pain  of  chest 
expansion prevents deep inhalation. Such pain control has been 
reported to facilitate postoperative respiratory therapy and reduce 
the incidence of pulmonary complications.
ii.  The  lack  of  blockage  of  sympathetic  outflow  is  of  particular 
significance. This lack of effect on vascular tone also accounts for 
the lack of  any postural  hypotension and has been reported to 
facilitate early patient mobility. Spinal local anesthetic block results 
in loss of efferent sympathetic activity when producing a reduction 
in  heart  rate  and  cardiac  output.  Such  blocks  serve  to  relax 
peripheral vascular beds resulting in a relative hypovolemic state.
iii.  The  perioperative  use  of  spinal  opiates  will  stabilize 
hemodynamics  by  preventing  the  reflex  mediated  hypertensive 
response evoked by particularly intense surgical stimuli.
iv. Pain associated with the metastasis of cancer, low back pain or 
ischemic pain associated with peripheral vascular  disease has 
been  shown  to  be  reduced  significantly  by  the  spinal  action  of 
opiates.23
Side  effects  of  Intrathecal  Opioids:  The  4  classic  side 
effects  are  pruritis,  nausea and vomiting,  urinary retention and 
respiratory  depression.  Most  side  effects  are  dose  dependent. 
Side effects are less common in patients chronically exposed to 
either intrathecal,  epidural on systemic opioids. Some side effects 
are mediated via interaction with specific opioid receptors while 
others are not.
1.  Respiratory depression:  Delayed respiratory depression after 
intrathecal morphine for post operative pain was reported towards 
the end of 1979 independently by Glynn et al and by Liolios and 
Anderson.19
Definition:  From a pathophysiologic  point  of  view,  respiration is 
depressed if the subject fails to respond adequately, on a moment to 
moment  basis  to  hypercapnia  or  hypoxia.  Central  respiratory 
depression exists when the respiratory neurons of the medulla fail to 
respond appropriately to these stimuli.
Spinal opioids result  in respiratory depression primarily by 
direct  depression  of  the  respiratory  nuclei  and  the 
chemosensitive  areas  of  the  brain  stem17.  Onset  of  respiratory 
depression  after  intrathecal  administration  seems  to  be  quite 
variable.  Almost  all  cases  with  intrathecal  morphine  may  be 
delayed  for  hours.  The  incidence  of  respiratory  depression 
requiring intervention following conventional doses of intrathecal 
and epidural opiates is approximately 1% which is the same as that 
following  conventional  dosing  of  intramuscular  and  intravenous 
opioids.
Early  respiratory  depression  occurs  within  2  hours  of 
injection of opioid. Most reports of clinically important respiratory 
depression involve administration of  epidural  fentanyl  or epidural 
sufentanil and are very rare following the intrathecal use of fentanyl 
or sufentanil. It likely results from systemic absorption of the drug. 
However,  cephalad migration of opioid in CSF may also initiate 
early respiratory depression.
Delayed respiratory depression occurs more than 2 hours 
after injection of opioid.  All  reports of clinically relevant  delayed 
respiratory  depression  involve  administration  of  intrathecal  or 
epidural morphine. It results from cephalad migration of opioid in 
CSF and subsequent interaction with opioid receptors located in 
the  ventral  medulla.  Delayed  respiratory  depression 
characteristically  occurs  6-12  hours  following  intrathecal  or 
epidural administration of morphine and may persist for 24 hours.
Bradypnea appears to be a more reliable clinical  sign of 
early respiratory depression following intrathecal or epidural use of 
fentanyl or sufentanil. Pulse - oximeter may be valuable but must be 
interpreted  cautiously  if  supplemental  oxygen  is  being 
administered.  The  most  reliable  clinical  sign  of  respiratory 
depression appears to be a depressed level  of  consciousness, 
possibly  caused  by  hypercarbia.  Most  protocols  for  monitoring 
assess patients hourly for 4-6 hours if fentanyl or sufentanil  has 
been  administered  and  for  18-24  hours  with  morphine. 
Concomitant use of any intravenous sedative increases the risk. 
Treatment involves administration of supplemental oxygen with 
mask and, encourage the pt to breathe, if the above measures 
are not helpful an opioid receptor antagonist, usually naloxone is 
administered. 
2.  Urinary  retention:  The  failure  to  achieve  spontaneous 
micturition,  for periods sufficient to require catheterization (10-20 
hours)   has   been   observed   following   spinal   opiates   in 
postoperative and chronic  pain patients23.  The incidence varies 
widely from 0 -80% and the incidence is higher when intrathecal 
morphine is utilized. It  is most likely related to interaction with 
opioid  receptors  located  in  the  sacral  spinal  cord.  This 
interaction promotes inhibition of sacral parasympathetic nervous 
system  outflow which causes detrusor muscle relaxation and an 
increase in maximum bladder capacity leading to urinary retention.
3.  Pruritis:  Is  defined  as  subjective,  unpleasant  &  irritating 
sensation arising from superficial layers of the skin that provokes 
an urge to scratch.28
The most common side effect  of  intrathecal  and  epidural 
opioids is pruritis. The incidence varies widely from 0 to  100%. It 
may be generalized but is more likely to be localized to  the face, 
neck  or  upper  thorax.  The  incidence  may  be  higher  when  the 
intrathecal  route  is  utilized  and  is  lower  following  subsequent 
doses. The  sensation  appears  around  or  just  after  the 
development of analgesia by either epidural or intrathecal opiate 
injection and normally continues (when it occurs) for the duration of 
the  analgesia.  Pruritis  is  more  likely  to  occur  in  obstetric 
patients which may result  from an interaction of oestrogen with 
opioid receptors.
Pruritis induced by intrathecal and epidural opioids is likely 
due to cephalad migration of the drug in CSF and subsequent 
interaction with the trigeminal nucleus located superficially in the 
medulla.  Opioid receptors  are present  in the trigeminal  nucleus 
and trigeminal nerve roots. The most common location of induced 
pruritis is in the facial areas innervated by the trigeminal nerve.
Altered central nervous system perception of pain may also 
play  a  role.  The  trigeminal  nucleus  descends  into  the  cervical 
region  of  the  spinal  cord  and  becomes  continuous  with  the 
substantia gelatinosa of the dorsal horn. Opioid interaction in the 
substantia  gelatinosa  may thus  initiate  an  "itch  reflex"  through 
indirect  action  on  the  trigeminal  nucleus. Use of  a  single  dose 
ondansetron 8 mg has been shown to be effective in prevention of 
intrathecal morphine induced pruritus. In addition to 5HT3 binding, 
ondansetron also binds at u receptors as an antagonist. Since the 
u  opioid  receptors  system is  also  involved  in  the  regulation  of 
intrathecal morphine induced nausea and vomiting, ondansetron 
may exert its anitemetic action at this level. 
4. Nausea and Vomiting:  The rate of occurrence of nausea and 
vomiting  in  postoperative  patients  is  around  15-35%.23 the 
incidence  of  nausea  and  vomiting  following  intrathecal  and 
epidural opiates in approximately 30%. It is likely the result of 
cephalad migration of  drug in CSF and subsequent  interaction 
with opioid receptors located in the vascularized area postrema 
lying superficially on the floor of the 4th ventricle. Sensitization of 
the vestibular system to motion and decreased gastric emptying 
produced by opiates  may also play a role.  Tolerance  occurs 
rapidly  as  the  incidence  of  vomiting  is  reduced  with 
subsequent administration
Adjuvants  to  local  anesthetics:  Experimental  effects  of 
intrathecal  opiates  show that  combinations of  opiates  and local 
anesthetics are synergistic for somatic analgesia in animal models 
and that intrathecal opiates can markedly enhance analgesia from 
sub therapeutic doses of spinal lignocaine.24
The  addition  of  epinephrine  and  narcotics  to  hyperbaric 
spinal  anesthetic  solutions  produces  significant  changes  in  the 
baricity  of  these  solutions.  These  changes  in  baricity  might 
produce  spinal  anesthetic  levels  more  characteristic  of  isobaric 
spinal solutions.25
Belzarena  et  al,  in  their  study  found  that  morphine,  a 
lipophobic  opioid agonist,  when administered via the subarachnoid 
route,  provides longer lasting analgesia than fentanyl.  Lipophilic 
opioids  (e.g.  fentanyl)  have  a  very  fast  onset  compared  with 
lipophobic  opioids  (e.g.  morphine)  and  when  administered 
together with a local anesthetic, many of their clinical actions can 
happen during the intraoperative period.26
In  further  studies,  he  concluded  that  the  combination  of 
bupivacaine  with  intrathecal  morphine  provides  excellent  post 
operative  analgesia  and  very  few  undersirable  side  effects  for 
women undergoing caesarian section.26
Wang  et  al  have  shown  that  bupivacaine  alone  or  in 
combination  with  opioids  provide  adequate  pain  relief  without 
motor  paralysis.  Local  anesthetics  in  conjunction  with  opioids, 
administered spinally provide good analgesia in patients in labour 
with less  intense  motor  blockade  than  that  produced  by  local 
anesthetics  alone.  Previous  studies  in  animals  indicated  that 
opioids  and  local  anesthetics  administered  spinally  have  a 
synergistic analgesic effect, but opioids do not enhance the motor 
blockade induced by the local anesthetics. Hypotension  caused 
by sympathetic blockade can be another major unwanted effect of 
local anesthetics. Opioids do not cause significant depression of 
the  efferent  sympathetic  pathway  and  motor  function  but 
administered  alone,  their  analgesic  efficacy  is  often  inadequate 
compared with that provided by local anesthetics.24
Opioid  u  agonists  open  K+  channels  presynaptically  to 
inhibit transmitter release and thus reduce Ca+ influx and have  a 
direct  postsynaptic  effect,  causing  hyperpolarization  and  a 
reduction  in  neuronal  activity.  It  has  also  been  suggested  that 
opioids may affect Ca+ flux directly. Local anesthetics act mainly by 
blockage  of  voltage  gated  Na+  channels  in  the  axonal 
membrane. They may also have effects on synaptic transmission i.e. 
a  presynaptic  inhibition  of  calcium  channels,  in  addition  to  their 
effects  on nerve conduction.  Clearly,  a combination of  these 
effects  may  explain  the  observed  synergism  between  local 
anesthetics and opioids, as originally suggested by Fraser et al.24
Physicochemical  properties and actions of opioids and local 
anesthetics:  There are similarities in molecular weight and pKa 
between  local  anesthetics  and  opioids.  The  phenylpiperidine 
derivatives (pethedine, fentanyl, lofentanil) are closest in structure 
to local anesthetics. The rate of absorption of Pethedine from the 
epidural space is similar to that of lignocaine and like lignocaine, 
has a rapid onset of analgesia after epidural use that coincides 
with  early  peak Pethedine  concentrations  in CSF.  Fentanyl  and 
lofentanil are highly lipid soluble. This property should promote rapid 
onset of action with minimal residual CSF concentrations of  drug 
that could be available to migrate to brain. In contrast,  morphine 
has lower lipid solubility. It has a slow onset of action after epidural 
use that coincides with delayed peak concentrations of   morphine 
in    CSF and its  relative  hydrophilicity  results  in  slower  efflux 
from   the   spinal   cord   and CSF resulting   in greater migration 
to the brain.  At pH 7.4 the tertiary  amine group  in  each  of  the 
opioids  is  mostly  ionized,  making  the  molecule  more  water 
soluble.  Additionally  in  the case of  morphine,  hydroxyl  groups 
on the molecule confer significant water solubility, so that  is why 
morphine base is much more water soluble than any other  opioid 
base in clinical use.
Studies point to presynaptic and postsynaptic receptors in 
the substantia gelatinosa of the dorsal horn of the spinal cord as a 
major site of  action of  spinally administered opioids.  In contrast, 
local  anesthetics  act  by  axonal  membrane  blockade, 
predominantly in the spinal nerve roots.
The major  advantages  of  "selective"  blockade of  pain  by 
spinal  opioids lies in the absence of sympathetic blockade and 
postural  hypotension,  potentially  allowing  easy  ambulation  of 
patients and avoidance of cardiovascular collapse or convulsions, 
the major  complications of  local  anesthetic  blockade.  However, 
early and later respiratory depressions are major concerns with 
spinal opioids.
Side effects causing discomfort can result from both classes 
of  drugs,  with  nausea and vomiting  being  more  common from 
opioids and urinary retention similar from both classes of drugs, 
although  tolerance  to  this  effect  develops  with  opioids  and  is 
antagonized by naloxone. Only spinal opioids appear to cause the 
strange phenomenon of pruritis.
Bupivacaine:  is  an  aminoacyl  amide  synthesized  by  Bo  af 
Ekenstam. First reports of its use were made in 1963. Bupivacaine is 
3-4 times as potent as lignocaine and considerably longer lasting. 
Its speed to onset is marginally slower.
Fig. 1
Bupivacaine  is  highly  protein  bound.  The  first  pass  pulmonary 
extraction is dose depedent. Debutylation of bupivacaine results in 
the production of  a xylidide metabolite  which undergoes further 
breakdown.27
Morphine 
Fig.2
Chemistry
Morphine  is  the  prototype  opioid  antagonist  to  which  all 
other  opioids  are  compared.  It  is  classified  under  phenathrene 
group  of  opioids.  The three  rings of  phenanthrene  nucleus  are 
composed of 14 carbon atoms. 
Mechanism of action
Opioids are unique in producing analgesia without loss of 
touch, proprioception, or consciousness. Analgesia is produced by 
both  interaction  of  morphine  with  μ  receptors  present  in  spinal 
cord  lamina  I,  II,  and  V  and  also  by  systemic  absorption  of 
morphine from spinal spaces.
Binding properties of morphine to opioid receptors
μ δ қ
Affinity Activity Affinity Activity Affinity Activity
Morphine +++ +++ ++ +- + +
Cephalad  movement  of  opioids  in  the  cerebrospinal  fluid 
(CSF)  principally  depends  on  their  lipid  solubility.  Morphine 
remains in the CSF for cephalad transfer by bulk flow, reaching 
the  cistrna  magna  in  1  to  2  hours  and  the  fourth  and  lateral 
ventricles by 3 to 6 hours29. Coughing or straining, but not body 
position,  can  affect  movement  of  CSF.  Elimination  half  time of 
morphine in CSF is similar to that in plasma30.
Preservatives 
As early as 1954, Moore et al advised that local anesthetic 
administered  epidurally  should  be  free  of  preservatives. 
Malinovsky et al suggests that "neurotoxicity can result from the 
use of adjuvants." Some authors suggest that arachnoiditis occurs 
as a result  of the vasoconstrictive component of the anesthetic, 
whilst  others  say  that  contaminants  or  preservative  agents  are 
responsible.
It must be stressed that any drug preparation injected in to 
the  spine,  may  contain  preservatives  such  as  benzyl  alcohol, 
polyethylene glycol, and chlorobutanol (a derivative of chloroform) 
and  that  these  carry  a  risk  of  neurotoxic  effects.  Another 
preservative  that  can cause reaction  is  sodium bisulfate,  which 
may trigger a severe allergic reaction if the patient is susceptible. 
Usually  the  injectable  form  of  morphine  sulfate  contains 
0.5% chlorobutanol  and  not  more  than  1% sodium bisulfate  in 
every ml of morphine sulfate injection USP. Malinovsky JM etal 
showed that  0.05% chlorobutanol  injected intrathecally  "induced 
significant severe spinal cord lesions". It is therefore vital to ensure 
that preservative-free solution is used.
Morphine is recently made available in India as sterile, non-
pyrogenic,  preservative  free  aqueous  solution  in  ampolues 
containing 10mgs of the drug, 
MATERIAL AND METHODS
Following  approval  by  the  institutional  review  board  and 
institutional research grant committee, eighty patients presenting 
for  elective  abdominal  hysterectomy  were  included  in  this 
randomized,  double  blind  study.  A  pilot  study  was  initially 
conducted on 20 patients to obtain the sample size required for 
statistical estimation
Inclusion Criteria 
Patients of ASA 1 & ASA 2 physical status
Uterus < 24 weeks size
Patient willing to participate in the study 
Age 30-60 years
Exclusion Criteria
Patients of ASA 3 & ASA 4 physical status
Large uterus > 24 weeks size               
Age>60 years
Known allergy to the study drug
Morbid obesity
Previous complicated abdominal surgeries 
Patient not willing for spinal Anesthesia and study
Other  contraindication  for  spinal  Anesthesia  such  as 
coagulopathy, systemic or local infection   
Preoperative Preparation
             All the patients were seen by the anesthetist on the day 
prior  to  surgery.  The  procedure  was  explained  and  informed 
consent  obtained.  The  visual  analogue  scale  (VAS)  and  post 
operative nausea and vomiting (PONV) score was explained to 
the patients. All patients received tablet ondansetron 8 mg orally 
along  with  benzodiazepine  one  hour  prior  to  surgery  as 
premedication.
         
c. Method of randomization:
 The patients were randomised to one of the 2 groups by a 
computer generated random assignment.  
d. Method of allocation concealment
The  investigator  who  was  giving  the  drug  was  given  a 
sealed envelop mentioning the group and method of preparation 
of the drug. After the drug was administered it was recorded as 
bupivacaine with study drug 1 or 2. The envelop and the allocation 
sheet were destroyed.
e. Blinding and masking:  
This is a double  blind study as the participant  and outcome 
assesors were blinded to treatment allocation.
 PREPARATION OF THE DRUG
         All the drug solutions were prepared by an anesthesiologist 
who was not involved with the administration of spinal anesthesia 
or  with  observation  of  the  patients.  All  drugs  used  for  spinal 
anesthesia were autoclaved as per the departmental protocol. 3.5 
ml  of  hyperbaric  bupivacaine  0.5%  [heavy]  was  given  in  both 
groups along with preservative free morphine according to study 
group.  
PROCEDURE    
          In the operating room monitoring was established with pulse 
oximetry,  ECG,  non  invasive  blood  pressure. After  establishing 
intravenous (iv) access, patients were preloaded with 10 ml per kg 
of  crystalloids.  Under  aseptic  precautions,  and   patient  in  the 
lateral  position, lumbar subarachnoid block was established and 
the  study  drug  given  the  study  group   along  with  3.5  ml  of 
hyperbaric  local anesthetic bupivacaine 0.5% using   25 gauge 
Whitacre needle, following the intrathecal injection, patients was 
immediately placed supine Supplemental oxygen ( 4 litres /min ) 
was administered to all patients using a Hudson’s mask.  The level 
of sensory blockade was noted. In case of hypotension following 
spinal  Anesthesia  and  systolic  blood  pressure  of  less  than 
100mmHg or blood pressure  less than 80% from the baseline, iv 
fluids was administered along with bolus of injection ephedrine 5 
mgs boluses intravenously as required  
ASSESSMENT  OF  THE  PATIENT:  The  following  variables  were 
assessed and recorded in the operating room.
1 Dermatomal sensory blockade to pin prick was evaluated
2 Extent of motor block was quantified
3 Side effects of intrathecal morphine such as nausea, vomiting, 
pruritus,  arrythimias,  shivering,  bradycardia,  respiratory 
depression were recorded.
4 Hypotension  following  spinal  Anesthesia  was  recorded  and 
treated. 
5 Nausea and vomiting if present was noted and were treated 
with intravenous ondansetron  4 mg.
6 In the  post operative period, patients were monitored for the 
quality of pain relief and side effects such as nausea, vomiting, 
pruritus ,sedation, respiratory depression  at 0, 1, 2, 4, 8, 12, 
24  hours  Pain  was  assessed  using  visual  analogue  scale 
[VAS] with ‘0’ meaning “no pain” and 10 being the “worst pain 
imaginable”.
        Whenever the VAS score stayed more than 4, additional 
analgesia in the form of tablet ketorolac 10 mgs every 6 th hourly 
was given. Post operative nausea and vomiting (PONV) score was 
more  than  1  [i.e.  severe  nausea,  vomiting]  or  if  the  patient 
demanded,  intravenous  ondansetron  0.1  mg/kg  was  given. 
Pruritus was treated with Tab. chlorpheniramine maleate 25 mg on 
request.  Respiratory  depression  was  recorded  whenever 
respiratory rate was less than 10 per minute or oxygen saturation 
less than 90% and treated with oxygen by face mask at the rate of 
6L/  minute,  encouraging  the  patient  to  be  breathe  deeply. 
However  if  the  patient  was   not  responding   to  the  above 
measures, then naloxone 0.5 to 1 mcg/kg body weight was to be 
given intravenously and saturation monitoring continued. All these 
information were recorded in the proforma.
6.  All  patients  were  followed  up  for  complications  such  as 
headache,  like  PDPH  and  any  neurological  complications  until 
discharge. 
STATISTICAL METHEODS:                         
The data collected from the patients were entered in EXCEL 
sheet and statistical analysis was done using SPSS 11 software. 
Comparison of the mean between the two groups was done by 
Pierson chi-square test.  
RESULTS
The results for the 80 patients allocated to the two groups 
were analysed.
Group A received – 3.5 ml of 0.5% hyperbaric bupivacaine 
with 250 micro gms of morphine.
Group B received – 3.5 ml of 0.5% hyperbaric bupivacaine 
with 150 micro gms of morphine.
The data for all  the 80 patients  are shown in the master 
chart.
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Figure-2: Demographic Data - WEIGHT
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Table 1   Mean age in years
Variable Group An=40
Group B
n=40
Age  in  years 
SD
45.95
+ 5.53
45.3
± 4.90
The mean age in group A is 45.95 + SD 5.54 and in group B 
is     45.3 + 4.91.
There is no statistically significant difference in age between 
the two groups. 
  
Table 2 Mean weight in kilograms
Variable Group An=40
Group B
n=40
Weight in Kgs
55.3
+ 5.41
54.7
± 4.72
The mean weight in Group A is 55.3 kgs + 5.41 SD and in 
group B is 54.7 + 4.72 SD 
There  is  no  statistically  significant  difference  in  weight 
between the two groups. 
Figure-3: Demographic Data   - HEIGHT
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Figure -4 Mean Duration of Surgery in Hours
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Table 3   Mean Height in CMS
Variable Group An=40
Group B
n=40
Height in CMS
156.1
+ 3.31
156.02
± 2.80
The mean height in group A is 156.1 + 3.31 SD and in group 
‘B’ is 156.02 +  2.80 SD. 
There  is  no  statistically  significant  difference  in  height 
between the two groups.     
Table – 4 Mean Duration of Surgery
Variable Group An=40
Group B
n=40
Duration  of 
Surgery  in 
Minutes
102.7
+ 11.14
105.75
± 8.73
Duration  of  surgery  in  Group  A is  102.75  minutes  +  SD 
11.148 and in Group B is 105.75 minutes + 8.737. 
There is no statistically significant difference in duration of 
surgery between the two groups. 
Figure -5: Duration of Analgesia in Hours
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Figure -6: Nausea
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Table-5. Mean Duration of Analgesia
Variable Group An=40
Group B
n=40
P-Value
Duration  of 
Analgesia
18.725
+ 1.37
16.075
± 1.22
<=0.001
Duration of analgesia was taken as time to the first dose of 
rescue analgesia. In group A it is 18.725  + 1.38 and in Group B 
16.075 + 1.23 
There is statistically a significanct difference in the duration 
of analgesia between the two groups with a ‘p’ value of < 0.001.  
Table-6 Nausea
Variable Group A Group B
Nausea
8
(20%)
7
(17.5%)
20% of patients in Group A [8/40] and 17.5% of patients in Group 
B  [7/40]  had  nausea; there  is  no  statistical  difference  between 
Group A and Group B. 
Figure-7: Vomiting
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Figure-8 Pruritus
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Table-7 Vomiting
Variable Group An=40
Group B
n=40
Vomiting
1
(2.5%)
2
(5)
The incidence of vomiting in group A is 2.5% (1/40) and 5% 
(2/40) in group ‘B’. There is no statistically significant difference in 
the incidence of vomiting between the two groups. 
Table-8 Pruritus
Variable Group An=40
Group B
n=40
P-Value
Pruritus 
5
(12.5%)
3
(7.5%)
0.808
The incidence of pruritus in Group A is 12.5% (5/40) and 
group B 7.5% (3/40). There is no statistically significant difference 
in the incidence of pruritus among the 2 groups. 
Figure -9   Additional Dose of Ondansetron
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Figure-10 Chlorpheneramine Maleate
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Table-9 Additional Dose of Ondansetron
Variable Group An=40
Group B
n=40
P-Value
Additional Dose of 
Ondansetron
6
(15 %)
8
(20%)
0.556
15% (6/40) of patients in group A 20% and (8/40) of patients 
is group B required additional doses of ondansetron in addition to 
the 8th hourly doses. There is no statistically significant difference 
is  the  consumption  of  additional  ondensetron  between  the  two 
groups. 
Table-10 Chlorpheneramine Maleate
Variable Group An=40
Group B
n=40
P-Value
Chlorpheneramin
e Maleate 
2
(5%)
2
(5%)
1.00
Two patients received T-Chlorpheneramine maleate in each 
group, there is no statistical difference between the two groups 
Figure-11 T. Ketorolac 10mg.
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Figure-12 Sedation Score
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Table-11 Rescue Analgesia
Variable Group An=40
Group B
n=40
1 Dose 11 (27.5%) 7 (17.5%)
2 Dose 29 (72.5%) 33 (82.5%)
27.5% (11/40) patients in group A, 17.5% (7/40) patients in 
group  B  received  one  dose  of  rescue  analgesia  (ketorolac 
10mg),during  the  24  hours  for  pain  relief   while  29  patients  is 
group A (72.5%) and 82.5% (33/40) patients in group B received 2 
doses of rescue analgesia.  Even though there is no statistically 
significant  difference in the rescue analgesia,  all  patients  in the 
study groups required some oral NSAIDs for the first 24 hours as 
in both groups the duration of analgesia was less than 24 hours 
even with the higher dose of intrathecal morphine.
Table-12 Sedation Score
Variable Group An=40
Group B
n=40
Sedation Score 0 36 36
Sedation Score 1 4 (10%) 4 (10%)
10% patients in Group A (4/40) and 10% patients in Group 
B (4/40) had a sedation score of 1(drowsy and arousable). There 
is  no statistically significant  difference between the two groups. 
None of them had sedation scores more than 1.
Figure-13 Pethedine Injection
Patients recieved pethidine injection
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Table -13 Pethedine Injection
Variable Group An=40
Group B
n=40
P-Value
Pethedine 
Injection
1
(2.5%)
5
(12.5%)
0.090
1 patient (2.5%) in group A received injection pethedine and 
5 patients (12.5%) in group. Even though there is no statistically 
significant difference (p < 0.09), clinically a few patients’ required 
parenteral  opioids,  necessitating  additional  prescription  and 
nursing time. 
Respiratory Depression
None  of  the  patients  in  both  study  groups  had  clinically 
significant respiratory depression.
Post dural Puncture Head Ache
None of the patients in both study groups had complaints 
suggestive of post dural puncture headache (PDPH)
DISCUSSION
Spinal  Anesthesia continues to be one of the commonest 
regional anesthetic techniques because of its rapid onset, safety 
and simplicity. More and more anesthesiologists are administering 
drugs intrathecally to provide both intra-operative anesthesia and 
postoperative analgesia for various surgical procedures. 
Adequate postoperative pain management relieves suffering 
and leads to earlier mobilization, shortened hospital stay, reduced 
hospital  costs  and  increased  patient  satisfaction.  Pain  control 
regimens should not be standardized; they should be tailored to 
the needs of the individual patient taking into account his/ her age, 
medical, physical, psychological condition and the level of fear or 
anxiety.  But  the  general  goal  in  all  post-surgical  patients  is  to 
minimize exposure to side effects of prolonged or relatively high 
doses  of  systemic  narcotics  or  analgesics  while  providing 
adequate analgesia. 
Transabdominal  hysterectomy  is  a  frequently  performed 
operation with moderate to severe postoperative pain. The aim of 
our  study  is  to  compare  the  efficacy  of  two  different  doses  of 
intrathecal morphine, i.e 250 µgm and 150 µgm along with a local 
anesthetic in terms of duration of analgesia, time to the first dose 
of  rescue  analgesic,  total  dose  of  rescue  analgesic  and  the 
incidence  and  severity  of  side  effects  in  patients  undergoing 
transabdominal hysterectomy.  
In our country most of the transabdominal hysterectomies 
are  done  under  spinal  anesthesia.  Intrathecal  morphine  has 
proved useful  in the treatment of post  operative pain in various 
surgical  populations.  However,  there  are  only  few  studies  in 
literature  studying  its  efficacy  in  gynecological  procedures. 
Moreover  no study is available  regarding the use of  intrathecal 
morphine in the Indian population.  Hence we thought this study 
would benefit  this group because of the excellent analgesia it is 
thought to provide for the first 16-24 hours following surgery with 
minimal side effects as seen from Taeko Fukuda et al and others 
study. It is also a cost-effective option (Jeff Gadsen et al`s study45) 
Preservative-free  intrathecal  morphine  has  recently  been  made 
available  in  this  part  of  the  country  and  it  is  less  expensive 
compared to other opioids or analgesia.
Various  additives  are  added  intrathecally  to  improve 
analgesia and prolong the duration of analgesia, commonly used 
drugs  being  Fentanyl,  Pethedine,  Morphine,  Clonidine, 
Neostigmine,  Ketamine,  Butrophenol.  Among  the  opioids, 
morphine has more advantages38-43 compared to others because it 
is a highly ionizable and hydrophilic drug having a prolonged effect 
as a result  of  its rostral  CSF spread and slower disappearance 
from the C.S.F and spinal tissue Chadwick et al, have shown this 
to be true from their studies43.
Various  doses  of  intrathecal  morphine  have  been  tried 
ranging  from  0.075  mgs  to  0.5  mgs  for  providing  high  quality 
postoperative  analgesia39,43 lasting  up  to  24hrs.46 The  most 
commonly used doses are between 100 -300 micrograms. Palmar 
et  al  describes  a  ceiling  effect49,50 in  the  analgesic  dose  of 
morphine, after which side effects increase more than analgesia.37,
The results for the 80 patients allocated to the two groups 
were analyzed
There is no statistically significant  difference between the 
two groups in terms of age, height, weight. There is no significant 
difference in duration of surgery. So the groups were comparable 
in terms of demographic variables.
The mean duration of  analgesia  in  patients  who received 
250μgms of intrathecal morphine was 18.725 +1.38 hours while in 
patients  who received  150μgm it  is  16.075  +1.23 hours.  In  the 
post operative period, pain was assessed using the “Visual Analog 
Scale”.  Whenever  the  patient  had  VAS  more  than  4  or  when 
patient complained of pain, Tab Ketorolac 10mgs was given per 
orally.  Our  results  are  comparable  with  the  studies  by  Hiroshi 
yamaguchi et al  46 
Even though there was a statistically significant difference in 
the  duration  of  analgesia  between  the  two  groups,  clinically  2 
more hours of duration of analgesia may not be significant. But the 
number of patients who had complete analgesia during the first 
day was  more  in  the  250μgm group  compared to  the  150μgm 
group.  Jeff  Gadson et  al  describe pain of  hysterectomy as two 
components,  visceral and somatic, visceral  pain arises from the 
uterus which is best  taken care of  by NSAIDs and the somatic 
pain best taken care by opioid45. We wanted to asses the efficacy 
of intrathecal morphine as a sole analgesic in the treatment of post 
operative pain relief. Soute etal has shown that very low doses like 
40μgm  or  80μgm  of  intrathecal  morphine  along  with  NSAIDS 
provide good post operative analgesia after caesarian section.
Prolonged postoperative  analgesia  doesn’t  come with  out 
side  effects.  Cousins  M  J  et  al,  describes  nausea,  vomiting, 
pruritius, sedation, urinary retention and respiratory depression as 
side  effects  of  intrathecal  morphine.45,47, These side  effects  are 
mostly “nuisance factors” rather than life threatening.48    
Review  of  literature  shows  the  incidence  of  nausea  and 
vomiting with intrathecal morphine as 35 to 45%,56,61  In our study 
the percentage of PONV is 22.5% which is less when compared to 
the previous studies done by Jhi Joung Wang et al and others. 
Patients in our study belong to the high risk category of PONV, the 
risk factors being female sex, gynecological surgery, non smoker 
and parental opioids. All the patients in our study received 8 mgs 
T.  ondensetron  preoperatively  as  prophylaxis  for  PONV  and 
pruritus.  In  addition  to  that,  all  the  patients  received  4mgs 
ondansetron intravenously eighth hourly and whenever required. 
This was due to ethical concerns. Despite this, 8 patients in group 
A and 7 patients in group B had nausea and 1 patient in group A 
and 2 patients in group B had vomiting. 6 patients in group A and 
8 patients in group B required additional  doses of ondensetron. 
The fact that there was no significant difference in the incidence of 
PONV  between  the  2  groups  with  the  increased  intrathecal 
morphine dose of 250 μgm is in contrast to earlier studies by Dahl 
et al. This may be due to differences in surgical techniques and 
then ethnical population.31,44,65,71   Study by Jhi-Joung Wang et al, 
have shown that a single  dose of dexamethasone can prevent 
intrathecal morphine induced nausea and vomiting56. So it may be 
worthwhile  to  combine  preoperative  dexamethasone  and 
ondansetron for prevention of postoperative nausea and vomiting 
after intrathecal morphine administration.
Even  though  a  lot  of  patients  had  mild  pruritis,  only  five 
patients  from  Group  A  and  3  patients  in  Group  B  had  severe 
pruritis This is in contrast to the previous studies. Choi et al have 
shown  that  reducing  the dose of  intrathecal  morphine in  LSCS 
patients  from 200  mcg to  50  mcg did  reduce  the  incidence  of 
pruritus to half63.  In our study, 25% patients from each group had 
mild pruritius, which settled without treatment. This is much lesser 
compared to previous studies 57,63 This may be due to addition of 
prophylactic  ondansetron56.  Naloxone  has  been  shown  to  be 
effective by Chang Jong Jeong et  al74  but  none of  our  patients 
required  naloxone  and  we  were  able  to  treat  the  pruritius 
adequately  with  a  single  dose  of  chloropheneramine  maleate75. 
Heni  Ming  Yeng  et  al  have  shown  that  a  single  dose  of 
ondansetron  reduced  the  incidence  of  intrathecal  morphine 
induced pruritis.62 
Regarding  breakthrough  pain  and  parental  opioid 
consumption,  there  was  statistically  no  significant  difference 
between the two groups,  but  when this  was  required additional 
nursing time also came into play.
None  of  our  patients  showed  sedation  scores  more  than 
one i.e, [drowsy and arousable] and none of our patients required 
treatment. Sedation can sometimes be considered an advantage. 
It allows a calm intra operative and post operative course without 
other side effects. This sedation can sometimes cause profound 
drowsiness, which is undesirable for patients. 
Urinary retention is the commonest side effect of intrathecal 
opioids.  The  incidence  varies  widely  from  0-80%  and  the 
incidence is higher when intrathecal  morphine is used. Rawal et 
al  observed67 that  this is most likely related to interaction with 
opioid  receptors  located  in  the  sacral  spinal  cord.  This 
interaction promotes inhibition of sacral parasympathetic nervous 
system  outflow which causes detrusor muscle relaxation and an 
increase in maximum bladder capacity leading to urinary retention. 
Urinary retention may last for 20-24 hours. Urinary  retention was 
not  a  problem  in  our  patients  as  these  patients  are  routinely 
catheterized as a part of surgery.
There  is  a  lot  of  concern  about  delayed  respiratory 
depression  associated  with  intrathecal  morphine.  Delayed 
respiratory  depression  occurs  6-12  hours  following  intrathecal 
administration of morphine, and may persist  for 24 hours,  Wide 
ranges of intrathecal morphine from 0.05mgs-0.5mgs have been 
tried66 and  from  the  available  literature  it  has  been  shown  no 
respiratory depression occurred with doses less than 0.3 mgs 35-38
In many of the earlier studies and case reports respiratory 
depression was not objectively quantified or defined.55 In our study 
respiratory depression was defined as respiratory rate less than 
10 /minute and Spo2 less than 90%. None of our patients had any 
respiratory  depression  including  delayed respiratory  depression. 
The  incidence  of  delayed  respiratory  depression  requiring 
intervention  following  conventional  doses  of  intrathecal  and 
epidural opioids is shown to be less than 1% by Jacobson K, et 
al68. However the incidence of respiratory depression in obstetric 
population is less due to the effect  of  progesterone,  which is a 
respiratory stimulant. Detection of respiratory depression induced 
by  intrathecal  and  epidural  opioids  may  be  difficult.  Classical 
bradypnoea  may  or  may  not  be  present  and  hypercarbia  may 
develop despite a normal respiratory rate. Pulse-oximeter may be 
valuable  but  must  be  interpreted  with  caution  if  supplemental 
oxygen is being administered.  Respiratory rate is an insensitive 
means  of  monitoring  respiratory  depression  though  it  is  highly 
used. In fact the response to CO2 stimulation may be decreased in 
the face of a normal respiratory rate and apparently normal state 
of consciousness. Gustfson et al found the incidence of delayed 
respiratory depression to be 0.33% in their study.
Spinal  Anesthesia  is  often  associated  with  postdural 
puncture headache [PDPH]. In our study, none of the patients had 
PDPH.  This  may  be  due  to  older  age  group  and  intrathecal 
morphine masking the incidence of PDPH. Kang SB et al69 and 
Brad  Youngerman  et  al72 have  shown  that  lesser  number  of 
attempts  and  use  of  intrathecal  morphine  can  reduce  the 
incidence of PDPH. In a recent randomized trial by Lavir et al the 
incidence of PDPH was 36% in cutting needle group and 3% in 
pencil point spinal needle group73 
Over the last three years, the practice of spinal anesthesia 
has changed in our institution with the availability of 25 G pencil 
point needle and preservative free morphine. 
The incidence of PDPH in our institution in 2004 was 12.4%; 
and in 2007 it  was  7.9%. Many patients  had mild to  moderate 
PDPH  in  both  the  studies.  However  none  of  them  required 
epidural  blood patches. In our institution studies conducted with 
the use of Whitacre needle the incidence of PDPH was 4.6% vs 
10.9% with Quincke 25G needles. The lesser incidence of PDPH 
in  caesarian  sections  during  2007  when  compared  to  2004  is 
probably  due  to  the  use  of  Whittacre  needles  and  intrathecal 
morphine.  Studies  by  Balestrieri  PJ77 has  shown  that  use  of 
intrathecal morphine reduces the incidence of PDPH.
CONCLUSION
Our study showed that addition of 150µgms and 250µgms 
of  preservative  free  morphine  as  adjuncts  to  bupivacaine  local 
anesthetic  for  subarachnoid  block  prolonged  the  duration  of 
analgesia after transabdominal hysterectomy. 250µgms morphine 
with  local  anesthetic  resulted  in  a  statistically  significant  longer 
duration of analgesia compared to 150µgms. However, there was 
no  statistically  significant  increase  in  side-effects  in  this  group 
either. Urinary retention was not a problem as these patients are 
routinely catheterized as part of surgery. There was no evidence 
of  life-threatening  problems like delayed  respiratory  depression, 
the  dreaded  PDPH  or  any  other  complication  that  increased 
morbidity. Adverse effects were similar in both groups.
All  the  patients  in  both  groups  reported  good  surgical 
analgesia for the first 16-18 hours. Thereafter all patients in both 
the groups required only one or two doses of Ketorolac as rescue 
analgesic for the first 24 hours. Incidence of PDPH was nil despite 
the spinal Anesthesia,  probably due to the intrathecal  analgesia 
and this is definitely an advantage as far as the patient and costs 
are concerned. Morphine being less expensive compared to other 
analgesics  and  since  very  minimal  doses  are  required  via  the 
intrathecal  route,  this  is  also  a  less  costlier  method  of  post-
operative analgesia compared to continuous analgesic infusions 
and PCA while involving only the same amount of monitoring too. 
The incidence of pruritus in our study was found to be significantly 
lesser  than  in  other  studies.  This  may  have  been  due  to  the 
administration of ondansetron prophylactically before the onset of 
action  of  intrathecal  morphine  which  is  thought  to  reduce  the 
incidence and intensity of PONV and pruritis in patients receiving 
intrathecal opioids. 
Nearly  one-fourth  of  the  patients  in  both  groups  still  had 
PONV  despite  injection  ondansetron  prophylactically  and  8th 
hourly.  Since  our  group  of  patients  are  high  risk  for  PONV, 
addition  of  steroids  like  injection  dexamethasone  along  with 
ondansetron with the first dose may probably help. 
We conclude that 250µgms of preservative-free intrathecal 
morphine provides longer duration of analgesia when compared to 
150µgms morphine,  with  hardly  any  additional  adverse  effects. 
Since preservative free morphine is now freely available in India, 
250µgms  intrathecal  morphine  pre-emptively  along  with  local 
anesthetics  and  oral  NSAIDs  thereafter  round  the  clock  as 
required,  is  a  good  cost-effective  option  for  complete  post-
operative  analgesia  in  patients  undergoing  Transabdominal 
hysterectomy under subarachnoid block. 
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APPENDIX 1:
PATIENT INFORMATION SHEET
STUDY NO:
TITLE OF THE STUDY:
Evaluation  of  the  efficacy  of  150  mcgs of  intrathecal 
morphine  with  bupivacine  compared  to  250 mcgs  for  post 
operative  analgesia  following  abdominal  hysterectomy a double 
blinded randomized control study.
INSTITUTION:
Department  of  Anesthesia,  Christian  Medical  College  & 
Hospital.
NATURE AND PURPOSE OF STUDY: 
The purpose of this study is to compare the efficacy of 150 
mcgs of Intrathecal morphine vs 250 mcgs  of the same for post 
operative pain relief following abdominal hysterectomy and asses 
the  magnitude  of  side  effects.  You  are  going  to  undergo 
abdominal hysterectomy. This operation will be performed through 
a transverse incision in the lower abdomen.  To ensure that your 
operation  is  pain  free,  we  will  be  giving  you  medicines  [  local 
anesthetics] in to the spinal space through a small needle, so that 
the  nerves  are  anesthetized  and  you  don’t  feel  any  pain  or 
sensation through out the operation.
Normally  recovery  of  sensation  occurs  after  3-4  hrs  and 
patient  will  need  additional  drugs  to  ensure  pain  free  in  the 
immediate  post  operative  period.  However  the  addition  of 
preservative  free  morphine  to  the  local  anesthetic  drug  should 
provide  adequate  analgesics  for  16-24  hours  after  the  surgery 
although recovery of motor function is achieved after 4 hours. This 
means that patients will not need other additional pain killers after 
the operation and can be mobile.
How  ever  with  intrathecal  morphine  has  occasional  side 
effects  like  itching,  nausea,  vomiting,  urinary  retention  and 
decreased  rate  of  breathing  can  occur.  Available  literature  has 
shown  these  to  be  mainly  nuisance  side  effects.  You  will  be 
catheterised  during  the  first  24  hours  as  a  part  of  surgical 
requirement, so that urinary retention is not a concern. Respiratory 
depression  is  very rare  and can be readily  treated,  PONV and 
itching  will  be  taken  care  to  a  certain  extent  by  preoperative 
ondansetron,  if  at  all  these  side  effects  occur  you  can  ask  for 
rescue medicines. Hence the purpose of the study is to compare 
the  efficacy  of  150mcgs  of  intrathecal  morphine  Vs  250mcgs 
morphine.
If  you  are  willing  to  participate  in  the  study  you  will  be 
randomly allocated to one of the 2 groups and will receive either 
150mcgs  of  intrathecal  morphine  or  250mcgs  of  intrathecal 
morphine, The efficacy of the analgesic effect will  be measured 
using visual analogue scales [VAS] this will  be explained to you 
during the preoperative visit  and on the next day the quality  of 
analgesia will  be assessed using visual analogue scale This will 
be  recorded  and  compared.  You  may  have  itching,  nausea, 
vomiting,  delayed  respiratory  depression  and  urinary  retention. 
Rescue medication for the treatment of all these conditions will be 
available  in  the  ward  at  all  times  with  no  additional  expenses 
involved.
EXPECTED DURATION OF INVOLVEMENT
On the day of surgery and one day post operatively
BENEFITS OF THE STUDY
The outcome of the study will help us to know if 150mcgs of 
intrathecal morphine is as efficacious as 250mcgs and decrease 
the complication and will  provide the same quality  of  analgesia 
with lesser side effects when compared to 250 mcgs of morphine.
CONFIDENIALITY 
All  personal  details  identifying  you will  be kept  confidential  and 
only data relevant to the study will be stored and analysed.
     
CONSENT   FORM  FOR  THE  STUDY:
I am ________________and my hospital number is_______________.
The details of this study have been explained to me. I understand that 
this is voluntary and I am aware of the purpose of the proposed study 
conducted by _________________. I give my consent to be enrolled in 
this study.
Signature of the Patient / Guardian    Signature of the Anesthetist
Name of the patient :                        Signature of the witness
Hospital no.             :                            Name of the witness
Date                         :
APPENDIX 2:
PROFORMA
Intrathecal morphine in Abdominal hysterectomy for post operative 
pain relief- study
Group: Time of spinal
Indication for surgery:                              Rescue Analgesia:
Hospital no:                                           
Age:
Intra op events: hypotension/ arrhythmia/ bradycardia / pruritus/ nausea 
& vomiting/ 
time VAS PONV pruritus Resp depress sedation
antiemeti
c antipruritic
0
1
2
4
8
12
24
Patient satisfaction excellent/ good/ fair/ poor
Troublesome side effects (patient)
PONV                                                  
0        no nausea or vomiting               
1        nausea
2        vomiting 
SEDATION SCORE
 0       awake                                                                     
 1        mild (occ. Drowsy)
 2       moderate (freq drowsy)  
 3       difficult to arouse
If respiratory rate is < 10 / min, check SpO2, if < 90% O2 by face mask 
@ 6L/min
Prophylaxis for nausea or vomiting – ondansetron 8 mg IV q8h
In c/o severe pruritus-T Chlorpheniramine maleate 25 mg 
 
Inclusion criteria
ASA I and II patients
Exclusion  criteria: Morbidly  obese,  contra  indication  for  spinal 
anesthesia, allergy to any study drug, age>60 yrs
Premedication: tablet ondansetron 8 mgs tablet diazepam 10 mgs
L 2-3, 3-4, 25G Whitacre spinal needle.
In case of hypotension SBP < 100 mmHg or < 80% of base line value, 
Rx with fluid bolus, i/v ephedrine
APPENDIX 3:
MASTER CHART
Sl 
no Group Hosp no Age Wt Ht dur surg m VAS ANALH Sed score side eff drug 1 drug2 drug3 drug4 drug5 Resc anal pdph pethedine
1 B 201288D 45 49 150 110 4 15 0 0 0 0 0 0 0 2 0 0
2 A 197894D 37 72 157 90 5 20 0 1 0 0 0 0 0 1 0 0
3 A 199309D 43 45 153 145 5 19 0 0 0 0 0 0 0 1 0 0
4 A 984473A 45 55 155 125 5 18 0 0 0 0 0 0 0 1 0 0
5 B 185694D 41 52 156 130 4 16 0 0 0 0 0 0 0 1 0 0
6 B 176400D 48 60 156 110 4 16 0 0 0 0 0 0 0 2 0 1
7 B 933260D 52 55 154 95 4 20 1 2 1 0 0 0 0 1 0 0
8 A 180194D 55 50 152 115 5 19 0 0 0 0 0 0 0 2 0 0
9 B 196584D 38 52 155 120 5 18 0 1,2,3 1 2 0 0 0 1 0 1
10 B 240678D 42 58 156 100 5 15 0 0 0 0 0 0 0 2 0 0
11 A 163753D 45 55 150 95 5 21 1 1,3 1 2 0 0 0 1 0 0
12 A 853650C 48 52 152 90 5 19 0 1 0 0 0 0 0 2 0 0
13 B 222296B 52 56 154 105 4 16 0 0 0 0 0 0 0 2 0 0
14 A 146555D 39 52 155 110 4 20 0 0 0 0 0 0 0 2 0 0
15 A 151538D 41 55 158 110 4 18 0 0 0 0 0 0 0 2 0 0
16 B 055272C 54 52 154 100 4 16 0 0 0 0 0 0 0 2 0 0
17 A 157827D 46 51 153 90 5 20 0 1,3 1 0 0 0 0 1 0 0
18 A 949468C 39 55 156 95 5 21 1 0 0 0 0 0 0 2 0 0
19 B 117922D 45 59 158 110 4 16 0 1 1 0 0 0 0 2 0 0
20 B 176558D 46 60 160 115 4 15 0 0 0 0 0 0 0 2 0 0
21 B 176511D 48 59 158 100 5 14 0 0 0 0 0 0 0 2 0 0
22 A 175627D 40 62 160 90 4 18 0 0 0 0 0 0 0 2 0 0
23 A 181601D 56 55 155 95 5 19 0 0 0 0 0 0 0 2 0 1
24 B 178196D 46 54 152 100 4 15 0 1 1 0 0 0 0 1 0 0
25 B 447525B 42 58 158 105 5 16 0 0 0 0 0 0 0 2 0 0
26 A 101217D 54 56 154 100 4 20 0 1 0 0 0 0 0 2 0 0
27 B 128682D 39 55 156 110 5 18 0 1,3 1 2 0 0 0 1 0 0
28 B 183631D 45 52 154 110 5 16 0 0 0 0 0 0 0 2 0 0
29 B 084204D 43 54 158 120 5 17 1 0 0 0 0 0 0 2 0 0
30 A 144424C 54 56 159 110 5 19 0 0 0 0 0 0 0 2 0 0
31 A 185694D 41 59 154 105 4 19 0 0 0 0 0 0 0 2 0 0
32 A 198057D 45 55 158 110 4 20 1 1,2 1 0 0 0 0 1 0 0
33 A 203429D 39 55 157 105 4 17 0 0 0 0 0 0 0 2 0 0
34 B 174333D 45 60 158 100 5 15 0 0 0 0 0 0 0 2 0 1
35 B 077587B 52 55 157 120 5 15 0 0 0 0 0 0 0 2 0 0
36 B 234147D 45 52 154 110 5 16 1 1 0 0 0 0 0 2 0 0
37 A 078874d 46 50 152 100 5 20 0 1,3 1 0 0 0 0 1 0 0
38 A 689225C 48 55 155 110 4 18 0 0 0 0 0 0 0 2 0 0
39 B 191999D 38 52 154 100 4 17 0 1 0 0 0 0 0 2 0 0
40 A 194749D 45 50 155 110 5 18 0 0 0 0 0 0 0 2 0 0
41 A 177981D 40 55 158 100 5 19 0 0 0 0 0 0 0 2 0 0
42 B 192468D 41 50 154 90 4 18 1 1 0 0 0 0 0 2 0 0
Sl 
no Group Hosp no Age Wt Ht dur surg m VAS ANALH Sed score side eff drug 1 drug2 drug3 drug4 drug5 Resc anal pdph pethedine
43 A 201467D 45 55 159 95 4 15 0 0 0 0 0 0 0 2 0 0
44 B 143531D 40 54 154 100 5 16 0 0 0 0 0 0 0 2 0 0
45 B 237021D 38 59 157 105 5 17 0 0 0 0 0 0 0 2 0 0
46 A 250801D 43 62 160 100 4 19 0 0 0 0 0 0 0 2 0 0
47 A 243807D 49 64 162 110 5 18 0 1 0 0 0 0 0 2 0 0
48 B 220903D 48 60 159 115 4 15 0 0 0 0 0 0 0 2 0 0
49 B 195408D 39 59 157 100 5 16 0 1,2 1 0 0 0 0 1 0 0
50 A 193110C 42 54 155 105 5 19 0 0 0 0 0 0 0 1 0 0
51 B 257773D 55 50 154 90 5 17 0 0 0 0 0 0 0 2 0 1
52 A 945473A 50 48 152 95 5 20 0 1,2,3 1 0 0 0 0 1 0 0
53 A 9905004C 56 50 154 90 5 19 0 1 0 0 0 0 0 2 0 0
54 B 320046B 52 48 152 95 4 17 0 0 0 0 0 0 0 2 0 0
55 B 182913D 48 45 154 100 4 15 0 0 0 0 0 0 0 2 0 0
56 B 386910B 46 52 158 110 5 16 0 0 0 0 0 0 0 2 0 0
57 A 258518D 55 56 156 100 5 20 1 1 0 0 0 0 0 2 0 0
58 A 256842D 46 54 154 105 5 21 0 0 0 0 0 0 0 1 0 0
59 B 684299C 48 50 156 100 4 16 0 0 0 0 0 0 0 2 0 0
60 A 752122A 42 49 154 90 4 19 0 0 0 0 0 0 0 2 0 0
61 B 067883D 54 50 155 100 5 17 0 0 0 0 0 0 0 2 0 0
62 B 053006D 48 59 158 110 5 15 0 0 0 0 0 0 0 2 0 1
63 A 173335B 39 62 160 100 4 19 0 1 0 0 0 0 0 2 0 0
64 A 172976C 45 65 162 120 4 20 0 1,2,3 1 2 0 0 0 1 0 0
65 B 267744D 42 60 160 110 5 18 0 0 0 0 0 0 0 2 0 0
66 A 212954D 55 56 158 105 5 17 0 0 0 0 0 0 0 2 0 0
67 A 275297D 55 56 154 100 5 16 0 0 0 0 0 0 0 2 0 0
68 A 356628C 45 52 156 90 4 18 0 0 0 0 0 0 0 2 0 0
69 B 869074C 38 50 154 105 4 14 0 0 0 0 0 0 0 2 0 0
70 B 075597D 42 45 152 100 5 16 0 1 0 0 0 0 0 2 0 0
71 B 090479D 45 59 163 100 4 15 0 0 0 0 0 0 0 2 0 0
72 A 051558D 42 55 159 110 5 18 0 1 0 0 0 0 0 2 0 0
73 B 380002B 45 52 154 100 4 17 1 3 1 0 0 0 0 1 0 0
74 A 045167D 41 50 152 105 5 16 0 0 0 0 0 0 0 2 0 0
75 A 001188D 48 58 160 100 4 17 0 0 0 0 0 0 0 2 0 0
76 B 089335D 43 65 162 110 4 16 0 1 1 0 0 0 0 2 0 0
77 A 589075B 49 66 165 100 5 18 0 0 0 0 0 0 0 2 0 0
78 B 114206D 52 62 160 120 5 15 0 0 0 0 0 0 0 2 0 0
79 B 115066D 42 55 156 100 4 15 0 0 0 0 0 0 0 2 0 0
80 A 113920D 45 50 154 90 5 18 0 0 0 0 0 0 0 2 0 0
APPENDIX-4
GLOSSARY
Hospital No : Hospital number 
Age : Age in years 
Weight : Weight in Kgs 
Height : Height in Cms 
Duration of surgery : Duration of surgery in Minutes 
VAS : Visual Analog Scale 
ANACH : Duration of analgesia in hours 
Sed. Score : Sedation score 
Resc anal : Rescue analgesia 
Pdph : Post dural puncture headache 
Side Effects
0 – No Side Effect
1 – Nausea
2 – Vomiting
3 – Pruritus
4 – Hypotension
5 – Shivering
6 – Bradycardia
7 – Respiratory Depressin
Sedation Score
0 – Awake
1 – Mild (occasionally drowsy)
2 – Moderate (Frequently drowsy)
3 – Difficult to arouse 
Drugs  
Drug-1 Ondansetron
Drug-2 Chlorphenramine maleate
Drug-3 Ephedrine
Drug-4 Pethedine
Drug-5 Atropine
Rescue Analgesia
0 – Nil
1 – One dose
2 – Two dose
